Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for P3 Health Partners (PIIIW) over the last 5 years, with Q3 2025 value amounting to $214.2 million.

  • P3 Health Partners' Non-Current Debt rose 6076.43% to $214.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.2 million, marking a year-over-year increase of 6076.43%. This contributed to the annual value of $108.9 million for FY2024, which is 54.28% up from last year.
  • P3 Health Partners' Non-Current Debt amounted to $214.2 million in Q3 2025, which was up 6076.43% from $102.0 million recorded in Q2 2025.
  • P3 Health Partners' 5-year Non-Current Debt high stood at $214.2 million for Q3 2025, and its period low was $80.0 million during Q1 2022.
  • Its 4-year average for Non-Current Debt is $112.2 million, with a median of $108.2 million in 2023.
  • The largest annual percentage gain for P3 Health Partners' Non-Current Debt in the last 5 years was 6076.43% (2025), contrasted with its biggest fall of 2341.28% (2025).
  • P3 Health Partners' Non-Current Debt (Quarter) stood at $94.4 million in 2022, then increased by 14.72% to $108.3 million in 2023, then grew by 0.54% to $108.9 million in 2024, then soared by 96.67% to $214.2 million in 2025.
  • Its Non-Current Debt stands at $214.2 million for Q3 2025, versus $102.0 million for Q2 2025 and $106.1 million for Q1 2025.